Germany's BRAIN Biotech 9M revenue falls 10.5% on core unit weakness

BRAIN Biotech AG

27/08/2026 06:42

Overview
Germany specialty enzymes provider's 9M revenue fell 10.5% yr/yr to €34.6 mln
Adjusted EBITDA for 9M declined to €-0.7 mln, mainly due to lower group revenues
Company cut outlook for BRAINBiocatalysts, raised forecast for BRAINBioIncubator segment

Outlook
BRAIN Biotech lowers forecast for BRAINBiocatalysts segment, now seeing revenue below prior-year level
Company expects BRAINBiocatalysts segment EBITDA margin below 10% for the year
BRAIN Biotech raises BRAINBioIncubator segment revenue forecast to around €6.0 mln, EBITDA at least €1.0 mln

Result Drivers
CORE SEGMENT WEAKNESS - Revenue decline driven by lower sales in BRAINBiocatalysts, especially baking enzymes, and production interruptions from facility relocation
MILESTONE PAYMENT IMPACT - BRAINBioIncubator segment benefited from a €1 mln milestone payment for the deucrictibant project, boosting revenue and margins
COST DISCIPLINE - Strict cost controls helped offset a larger negative earnings impact from lower revenue

Company press release: ID:nEQ51khHXa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
9M Revenue
 
EUR 34.60 mln
 
9M Adjusted EBITDA
 
-EUR 700,000
 
9M EBITDA
 
-EUR 2 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the environmental services & equipment peer group is "buy."
Wall Street's median 12-month price target for BRAIN Biotech AG is €5.00, about 78.6% above its August 26 closing price of €2.80

Reuters Recommended Reads
Aug 26 - German government cost cutting and red tape drive research abroad, chemical lobby says
Aug 26 - Germany's elumeo H1 revenue falls; EBITDA turns positive on cost cutting
Aug 25 - Molecular Partners H1 net loss narrows on lower R&D expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)